NEW YORK (GenomeWeb) – In a group of sponsored presentations at last week's annual meeting of the Association for Molecular Pathology, Thermo Fisher Scientific product users reported on their experiences in a variety of clinical areas, including liquid biopsy, immuno-oncology, and pharmacogenomics.

According to Anagh Vora, head of medical affairs for clinical NGS and oncology at Thermo Fisher is eager to strengthen its longstanding position as a technology supplier while increasing the implementation of its tools in clinical practice.